CST, 40804S, TNFRSF8/CD30 Antibody

Polyclonal Antibody for studying CD30. Validated for Western Blotting. Highly specific and rigorously validated in-house, TNFRSF8/CD30 Antibody (CST #40804) is ready to ship. Product Usage Information Western Blotting: 1:1000 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting Specificity / Sensitivity TNFRSF8/CD30 Antibody recognizes endogenous levels of total TNFRSF8/CD30 protein. Species Reactivity: Human Source / Purification Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human TNFRSF8/CD30 protein. Antibodies are purified by protein A and peptide affinity chromatography. Background TNFRSF8/CD30 is a type-I transmembrane glycoprotein that is a member of the TNFR superfamily. CD30 is synthesized as a precursor protein that undergoes extensive post-translational modification before becoming embedded in the plasma membrane as a 120-kDa transmembrane protein (1,2). The expression of CD30 is upregulated in activated T cells and may trigger costimulatory signaling pathways upon its engagement (3,4). While its expression is normally restricted to subsets of activated T cells and B cells, CD30 expression is robustly upregulated in hematologic malignancies, such as Hodgkin lymphoma (HL), anaplastic large cell lymphoma (ALCL), and adult T-cell leukemia, thus making it an attractive target for therapeutic intervention (5,6). Research studies have suggested that in certain disease contexts, CD30 recruits TRAF2 and TRAF5 adaptor proteins to drive NF-kappa B activation, aberrant cell growth, and cytokine production (7-9). CD30 signaling is also regulated by TACE-dependent proteolytic cleavage of its ectodomain, which results in reduced CD30L-dependent activation of CD30 cells (10,11). Alternate Names CD30; CD30 antigen; CD30L receptor; cytokine receptor CD30; D1S166E; Ki-1; Ki-1 antigen; Lymphocyte activation antigen CD30; TNF receptor superfamily member 8; TNFRSF8; TNR8; Tumor necrosis factor receptor superfamily member 8; tumor necrosis factor receptor superfamily, member 8 Specification REACTIVITY: H SENSITIVITY: Endogenous MW (kDa): 90 (precursor), 120 (mature) SOURCE: Rabbit